Trabectedin for soft tissue sarcoma

The Role of Trabectedin in Soft Tissue Sarcoma - PMC

Trabectedin has shown a favorable toxicity profile and is an alternative therapeutic option in patients with advanced STS.

Trabectedin (Yondelis) | Cancer information

Trabectedin is the name of a chemotherapy drug. It is also known as Yondelis. It is a treatment for: soft tissue sarcoma that has spread to other parts of the ...

Trabectedin for Patients with Advanced Soft Tissue Sarcoma

Trabectedin for patients with advanced soft tissue sarcoma: a non-interventional, prospective, multicenter, Phase IV trial.

A randomized phase III trial comparing trabectedin to best ...

The T-SAR study met its primary endpoint confirming that trabectedin reduces the risk of progression or death (regardless of cause) compared ...

FDA Approves Trabectedin for Sarcoma - NCI

On October 23, the Food and Drug Administration (FDA) approved trabectedin (Yondelis®) for the treatment of two subtypes of soft tissue ...

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic ...

Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they ...

A review of the Efficacy of Trabectedin as Second-Line Treatment of ...

Conclusion · For most patients with advanced soft tissue sarcoma (aSTS), the goal of second-line therapy is to achieve long-term efficacy with preserved quality ...

Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so ...

The authors report that the T-SAR trial showed improvement in progression-free survival (PFS) in patients with soft tissue sarcoma treated with ...

Trabectedin plus Durvalumab in Patients with Advanced Pretreated ...

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.

The Role of Trabectedin in Soft Tissue Sarcoma - Frontiers

Trabectedin has shown a favorable toxicity profile and is an alternative therapeutic option in patients with advanced STS.

3474-Soft tissue sarcoma advanced or metastatic trabectedin - eviQ

Soft tissue sarcoma advanced or metastatic trabectedin. The treatment of sarcoma is complex and combined modality therapy is common.

Update on the role of trabectedin in the treatment of intractable soft

In several clinical trials, the use of trabectedin in L-sarcomas has led to an improvement in patient outcome. However, the drug has also proven ...

Assessment of Safety and Efficacy of Combined Trabectedin and ...

Importance Active therapeutic combinations, such as trabectedin and radiotherapy, offer potentially higher dimensional response in second-line ...

Trabectedin for inoperable or recurrent soft tissue sarcoma in adult ...

This study evaluates the safety and effectiveness of trabectedin for patients with advanced STS who were treated at a high-volume sarcoma center.

Trabectedin for Soft Tissue Sarcoma: Current Status and Future ...

Trabectedin is an old new drug with proven potential to impact the lives of patients with soft tissue sarcoma and other solid malignancies.

Trabectedin in Soft Tissue Sarcomas - MDPI

Trabectedin is a synthetic, marine-derived alkylating agent derived from the Caribbean tunicate, Ecteinascidia turbinata [2]. The success of trabectedin in ...

Randomized Phase II Study of Trabectedin and Doxorubicin ...

Doxorubicin and trabectedin are considered active drugs in soft tissue sarcoma (STS). The combination of both drugs was hypothesized to be ...

Trabectedin - an overview | ScienceDirect Topics

Trabectedin was the first anticancer marine-derived drug to be approved in the European Union in 2007 for the treatment of patients with soft tissue sarcoma ...

Trabectedin as Second-Line Treatment in Advanced Soft Tissue ...

The European Society for Medical Oncology–European Reference Network for rare adult solid cancers clinical practice guidelines on sarcoma recommend trabectedin ...

Effectiveness and Safety of Trabectedin and Radiotherapy for ...

Myxoid liposarcoma (MLP) is a soft tissue sarcoma (STS) subtype that is characterized by specific genetic translocations producing FUS-DDIT3 or ...